Actively Recruiting
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Led by Eisai Korea Inc. · Updated on 2026-04-21
3000
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
CONDITIONS
Official Title
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Enrolled in JOY-ALZ registry before starting LEQEMBI treatment
- Clinical decision to treat with LEQEMBI has already been made
- Provides written informed consent for medical information sharing with Eisai Korea Inc.
You will not qualify if you...
- Currently participating in an interventional clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Eisai Trial Site #1
Nutley, New Jersey, United States, 07110
Actively Recruiting
Research Team
E
Eisai Korea Inc. Medical department Serena SoYoun Kwon
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here